← Back to All US Stocks

Lumexa Imaging Holdings, Inc. (LMRI) Stock Fundamental Analysis & AI Rating 2026

LMRI Nasdaq Services-Medical Laboratories DE CIK: 0002071288
Recently Updated • Analysis: Apr 12, 2026 • SEC Data: 2026-04-12
Combined AI Rating
HOLD
18% Confidence
STRONG AGREEMENT
HOLD
15% Conf
HOLD
20% Conf

📊 LMRI Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: HOLD with 15% confidence
Lumexa Imaging Holdings, Inc. (LMRI) receives a HOLD rating with 18% confidence from our AI fundamental analysis based on SEC 10-K filings. Below is our complete LMRI stock analysis for 2026.

Is Lumexa Imaging Holdings, Inc. (LMRI) a Good Investment?

Claude

Unable to conduct fundamental analysis due to absence of financial data across all major metrics (revenue, profitability, balance sheet, cash flow). The lack of recent financial transparency and data availability is a material concern for investors despite company's medical laboratory sector positioning.

ChatGPT

SEC filings presently provide no income statement, balance sheet, or cash flow details, preventing assessment of profitability, liquidity, or leverage. In a regulated, capital-intensive medical services niche, the absence of fundamentals argues for caution. Maintain a neutral stance until initial 10-Q/10-K data clarifies revenue traction, margins, and cash runway.

Why Buy Lumexa Imaging Holdings, Inc. Stock? LMRI Key Strengths

Claude
  • + Recent insider Form 4 filings indicate management engagement
  • + Nasdaq-listed company in healthcare services sector
  • + Medical laboratory services operate in recurring revenue environment
ChatGPT
  • + Nasdaq listing provides access to capital and impending disclosure cadence
  • + Exposure to medical diagnostics/services with durable, secular demand drivers
  • + Potential operating leverage if scale and utilization are achieved

LMRI Stock Risks: Lumexa Imaging Holdings, Inc. Investment Risks

Claude
  • ! No financial data available - complete lack of transparency
  • ! Data freshness marked as 'None' suggesting stale or missing SEC filings
  • ! Unable to assess profitability, solvency, or operational performance
  • ! Potential company distress, delisting risk, or filing non-compliance
ChatGPT
  • ! No financial statements available; profitability and solvency are unknown
  • ! Potential pre-revenue/high cash burn typical of early-stage healthcare services
  • ! Regulatory and reimbursement uncertainty common in medical diagnostics

Key Metrics to Watch

Claude
  • * Quarterly revenue and net income recognition
  • * Current ratio and working capital position
  • * Operating cash flow generation and free cash flow
ChatGPT
  • * Operating cash flow and cash runway
  • * Revenue growth and gross margin

Lumexa Imaging Holdings, Inc. (LMRI) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

LMRI Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

LMRI vs Healthcare Sector: How Lumexa Imaging Holdings, Inc. Compares

How Lumexa Imaging Holdings, Inc. compares to Healthcare sector averages

Net Margin
LMRI 0.0%
vs
Sector Avg 12.0%
LMRI Sector
ROE
LMRI 0.0%
vs
Sector Avg 15.0%
LMRI Sector
Current Ratio
LMRI 0.0x
vs
Sector Avg 2.0x
LMRI Sector
Debt/Equity
LMRI 0.0x
vs
Sector Avg 0.6x
LMRI Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Lumexa Imaging Holdings, Inc. Stock Overvalued? LMRI Valuation Analysis 2026

Based on fundamental analysis, Lumexa Imaging Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Lumexa Imaging Holdings, Inc. Balance Sheet: LMRI Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

LMRI Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

LMRI SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Lumexa Imaging Holdings, Inc. (CIK: 0002071288)

📋 Recent SEC Filings

Date Form Document Action
Apr 9, 2026 8-K d81221d8k.htm View →
Mar 30, 2026 10-K lmri_10k_2025.htm View →
Mar 26, 2026 8-K d138307d8k.htm View →
Mar 2, 2026 8-K d40982d8k.htm View →
Feb 27, 2026 4 xslF345X05/ownership.xml View →

Frequently Asked Questions about LMRI

What is the AI rating for LMRI?

Lumexa Imaging Holdings, Inc. (LMRI) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 18% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are LMRI's key strengths?

Claude: Recent insider Form 4 filings indicate management engagement. Nasdaq-listed company in healthcare services sector. ChatGPT: Nasdaq listing provides access to capital and impending disclosure cadence. Exposure to medical diagnostics/services with durable, secular demand drivers.

What are the risks of investing in LMRI?

Claude: No financial data available - complete lack of transparency. Data freshness marked as 'None' suggesting stale or missing SEC filings. ChatGPT: No financial statements available; profitability and solvency are unknown. Potential pre-revenue/high cash burn typical of early-stage healthcare services.

What is LMRI's revenue and growth?

Lumexa Imaging Holdings, Inc. reported revenue of N/A.

Does LMRI pay dividends?

Lumexa Imaging Holdings, Inc. does not currently pay dividends.

Where can I find LMRI SEC filings?

Official SEC filings for Lumexa Imaging Holdings, Inc. (CIK: 0002071288) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is LMRI's EPS?

Lumexa Imaging Holdings, Inc. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is LMRI a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Lumexa Imaging Holdings, Inc. has a HOLD rating with 18% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is LMRI stock overvalued or undervalued?

Valuation metrics for LMRI: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy LMRI stock in 2026?

Our dual AI analysis gives Lumexa Imaging Holdings, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is LMRI's free cash flow?

Lumexa Imaging Holdings, Inc.'s operating cash flow is N/A, with capital expenditures of N/A.

How does LMRI compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 12, 2026 | Data as of: 2026-04-12 | Powered by Claude AI